Stay updated on CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial
Sign up to get notified when there's something new on the CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial page.

Latest updates to the CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRemoved the MedlinePlus Genetics topic on Rheumatoid arthritis from the page.SummaryDifference0.2%

- Check21 days agoChange DetectedAdded a critical operating-status notice and a new version tag (v3.2.0) while removing the old version tag (v3.1.0).SummaryDifference3%

- Check28 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

- Check42 days agoChange DetectedVersion bump from v3.0.1 to v3.0.2 and removal of the 'Back to Top' element; no substantive changes to core content or pricing.SummaryDifference0.2%

- Check49 days agoChange DetectedThe web page has been updated from version 3.0.0 to 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.2%

- Check56 days agoChange DetectedThe web page has been updated to include specific facility names and locations, particularly highlighting Seoul, South Korea, and has added a significant reference to a recent study on infliximab in rheumatoid arthritis. Additionally, there are updates to the categorization of proteins and antibodies relevant to the content.SummaryDifference4%

Stay in the know with updates to CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CT-P13 SC vs IV in RA: Efficacy, PK, Safety Clinical Trial page.